Previous 10 | Next 10 |
SAN CARLOS, Calif. , April 13, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced preliminary operational and financial results for the quarter ended March 31 , 2020. Natera generated total revenue...
SAN CARLOS, Calif. , April 6, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing and non-invasive prenatal testing (NIPT) today announced an expansion in coverage of its Panorama test to all pregnant women, regardless ...
SAN CARLOS, Calif. , April 2, 2020 /PRNewswire/ -- A new, peer-reviewed case study published in JCO Precision Oncology 1 demonstrates the unique ability of Signatera technology to detect esophageal cancer recurrence almost one year before current standards of care, using a simple ...
SAN CARLOS, Calif. , March 19, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced expanded access to its virtual ordering platforms and remote testing capabilities across its reproductive, oncology and organ tra...
The following slide deck was published by Natera, Inc. in conjunction with their 2019 Q4 earnings Read more ...
By 2023, an estimated 3.5 million reproductive genetic tests will be performed annually in the United States. Driving the expanded use of these tests are updated guidelines from the American College of Obstetricians and Gynecologists and the American College of Medical Genetics. Can investors ca...
Image source: The Motley Fool. Natera (NASDAQ: NTRA) Q4 2019 Earnings Call Feb 26, 2020 , 4:30 p.m. ET Operator Continue reading
Natera Inc. (NTRA) Q4 2019 Earnings Conference Call February 26, 2020 16:30 ET CompanyParticipants Michael Brophy - CFO Steve Chapman - CEO Solomon Moshkevich - GM, Oncology & Transplant Bob Schueren - COO Conference Call Participants Max Masucci - Canaccord Genuity ...
SAN CARLOS, Calif. , Feb. 26, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the fourth quarter and the year ended December 31, 2019 and provided an upda...
SAN CARLOS, Calif. , Feb. 19, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2019 , after the market close on February 26, 2020...
News, Short Squeeze, Breakout and More Instantly...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2024, after the market close on Aug. 8, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET...
Study reports high accuracy of Signatera for surveillance of MCC patients, suggests potential to reduce frequency of surveillance imaging Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncolog...
2024-07-23 12:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...